MODERNA MRNA 深 沪
已收盘 10-11 16:00:00 美东时间
58.29
+1.460
+2.57%
华盛通- 最 高59.7342
- 今 开56.71
- 成交量 626.10万股
- 最 低 55.70
- 昨 收 56.83
- 总市值 222.08亿
- 52周最高 170.47
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 55.70
- 委 比 92.19%
- 总股本 3.81亿
- 历史最高 497.49
- 量 比 1.39
- 振 幅 7.10%
- 历史最低 11.54
- 每 手 1
- 风险率 23.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cosmo Pharmaceuticals gets new finance chief
Cosmo Pharmaceuticals (OTCPK:CMOPF) appointed Svetlana Sigalova as its new CCFO, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Prior to Moderna, ...
10-11 17:35
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could revolutionize cancer treatment, joining in the global trend as pharmaceutical companies across the world turn to oncology for economic growth and opportunity to make history.
10-11 02:00
Novavax gets EU authorization for updated COVID-19 vaccine
Novavax (NASDAQ:NVAX) has received marketing authorization from the European Commission for its updated 2024-2025 Nuvaxovid COVID-19 vaccine for use in people aged 12 years and older. Novavax said the...
10-09 23:51
What's Going On With Novavax Stock Today?
Novavax Inc (NASDAQ:NVAX) shares are bouncing around Wednesday, pulling back after popping in early trading. The company announced that it received European marketing authorization for its Nuvaxovid COVID-19 vaccine.
10-09 22:43
(MRNA) - Analyzing Moderna's Short Interest
Moderna's (NYSE:MRNA) short percent of float has risen 7.75% since its last rep...
10-09 03:15
RSV疫苗在美销量大降 “最有想象力产品”遭CDC重击
①独立药剂师表示，秋季接种RSV疫苗的需求比一年前下降了三分之二；②去年9月份，平均每周约有44万人接种了葛兰素史克或辉瑞的RSV疫苗；而今年9月份，每周的平均人数约为15.7万人。
10-08 23:23
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to b...
10-08 21:07
GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons in ...
10-08 20:32
2024年诺奖出炉，核酸药物龙头艾美疫苗（06660.HK）一骑绝尘
就在昨晚，全球瞩目的2024年诺贝尔生理学或医学奖重磅揭晓！Victor Ambros博士和Gary Ruvkun博士因发现microRNA及其在转录后基因调控...
10-08 09:01
